Skye Bioscience, Inc.
Skye Bioscience, Inc. (Nasdaq: SKYE) is a clinical-stage biotechnology company developing molecules that modulate G-protein-coupled receptors to treat obesity, overweight and metabolic disorders. Its lead candidate, nimacimab, is a humanized antibody that targets the cannabinoid receptor 1 (CB1) and is designed to… From the company’s description.
In fiscal 2025, Skye Bioscience, Inc. reported a net loss of $55.92M. Operations used $43.06M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Skye Bioscience, Inc. does
In the company’s own words
Skye Bioscience, Inc. (Nasdaq: SKYE) is a clinical-stage biotechnology company developing molecules that modulate G-protein-coupled receptors to treat obesity, overweight and metabolic disorders. Its lead candidate, nimacimab, is a humanized antibody that targets the cannabinoid receptor 1 (CB1) and is designed to inhibit the receptor outside the brain. The company is evaluating nimacimab as a standalone treatment and in combination with incretin-based therapies such as semaglutide; its CBeyond Phase 2a study enrolled adults with obesity or overweight. Skye operates as a single business focused on research and development, with no reportable segments described. It acquired nimacimab through its August 2023 acquisition of Bird Rock Bio. The company relies on third-party manufacturers to supply the candidate for preclinical and clinical studies, and its portfolio centers on nimacimab. In fiscal 2025, Skye reported no commercial product business and continued clinical development of its candidate. Its website is https://www.skyebioscience.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1516551
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Skye Bioscience, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Skye Bioscience, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Skye Bioscience, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Skye Bioscience, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Skye Bioscience, Inc.'s last four quarterly filings that the numbers alone won't show?”